title: Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients.
abstract: Acute myeloid leukemia (AML) is a heterogeneous disease with different clinical course and prognosis. microRNA-29 (miR-29) family of non-coding small RNAs can play an important role in pathogenesis of AML, but also can influence response to therapy.The purpose of the study was to evaluate miR-29c expression in AML patients in relationship to clinical parameters and response to chemotherapy, including azacitidine.
  
  
  METHODS
  miR-29c expression has been analyzed using RT-PCR in 95 bone marrow specimens from newly diagnosed AML patients in comparison to 20 healthy subject.
  
  
  RESULTS
  We showed up-regulated miR-29c expression in AML patients which was linked also to higher risk of disease relapse after achieving complete remission. In subset of elderly AML patients treated with azacitidine, low miR-29c expression at diagnosis correlated with good response to therapy.
  
  
  CONCLUSIONS
  miR-29c is of prognostic value and influences response to azacitidine treatment in older AML patients.
authors: Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.|Department of Physiology, Wroclaw Medical University, Wroclaw, Poland.
authors: Aleksandra
authors: A
authors: Butrym
authors: Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
authors: Justyna
authors: J
authors: Rybka
authors: Department of Forensic Medicine, Molecular Techniques Unit, Wroclaw Medical University, Wroclaw, Poland.
authors: Dagmara
authors: D
authors: Baczyńska
authors: Department of Internal, Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, Wroclaw, Poland.
authors: Rafał
authors: R
authors: Poręba
authors: Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
authors: Kazimierz
authors: K
authors: Kuliczkowski
authors: Department of Internal, Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, Wroclaw, Poland.
authors: Grzegorz
authors: G
authors: Mazur
mesh_terms: D000208:Acute Disease; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001374:Azacitidine / Q000627:therapeutic use*; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D053208:Kaplan-Meier Estimate; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000964:Antimetabolites, Antineoplastic; C532045:MIRN29a microRNA, human; D035683:MicroRNAs; D001374:Azacitidine
keywords: acute myeloid leukemia; azacitidine; expression; miR-29c; response to therapy